Alzamend Neuro, Inc.
ALZN
$2.96
-$0.03-1.00%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.50% | -31.59% | -48.52% | -55.54% | -53.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.75% | -66.04% | -61.53% | -51.99% | -33.17% |
| Operating Income | 54.75% | 66.04% | 61.53% | 51.99% | 33.17% |
| Income Before Tax | 54.61% | 65.92% | 61.42% | 51.89% | 33.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.61% | 65.92% | 61.42% | 51.89% | 33.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.61% | 65.92% | 61.42% | 51.89% | 33.14% |
| EBIT | 54.75% | 66.04% | 61.53% | 51.99% | 33.17% |
| EBITDA | 55.03% | 66.34% | 61.77% | 52.24% | 33.41% |
| EPS Basic | 85.74% | 83.53% | 71.28% | 54.62% | 35.19% |
| Normalized Basic EPS | 86.47% | 83.62% | 71.34% | 54.62% | 35.19% |
| EPS Diluted | 85.74% | 83.53% | 71.28% | 54.62% | 35.19% |
| Normalized Diluted EPS | 86.47% | 83.62% | 71.34% | 54.62% | 35.19% |
| Average Basic Shares Outstanding | 499.67% | 294.86% | 118.29% | 8.49% | 4.08% |
| Average Diluted Shares Outstanding | 499.67% | 294.86% | 118.29% | 8.49% | 4.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |